Dr. Palmer is an internationally renowned hepatologist and an experienced biotech/pharma executive. She is currently CEO Liver Consulting LLC, where she provides insight to the biotech and pharmaceutical industry fostering a path forward for the development of innovative medications for liver disease with high unmet medical need. Since 1991, she has served as a consultant to more than 50 biotech and pharma companies in numerous capacities as a liver disease expert.
Dr. Palmer was in a solo practice devoted to treating and evaluating patients with MASH, viral, and cholestatic liver diseases until 2009 at which time she became a Clinical Professor at NYU Langone and Director of Hepatology at NYU Langone Medical Center at Plainview. Dr. Palmer left NYU Langone to become Senior Vice President of Clinical Research and Head of Hepatology at Kadmon Corporation, where she developed their liver disease programs. She joined Shire in 2015 as Global Development Lead of Hepatology in addition to forming and leading the liver safety group. When Shire was acquired by Takeda in 2019, Dr. Palmer was recruited by Takeda, to become Head of Liver Disease Development. After leaving Takeda, Dr. Palmer, she was CMO of Gannex/Ascletis and advanced their multiple liver disease assets.
Dr. Palmer received her B.A. in biology from Columbia University and her M.D. from Mount Sinai School of Medicine in New York. She has been the primary or senior author of numerous manuscripts related to hepatology, which have been published in peer-reviewed journals.